Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
14,337 people get ABT articles and Market Currents by email alert.
Get email alerts on ABT »
HEADLINES:
ALL
|
PRO
|
FOCUS
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
-
-
-
-
-
-
-
-
-
-
-
-
-
At These Levels, Covidien Has Room To RunStephen Barnes • Tue, Apr 30 -
-
-
-
-
To learn more about Seeking Alpha Pro, click here.
-
-
-
-
-
-
-
-
-
-
-
-
Abbott Hopes Mitral Repair Will Be The New TAVIEP Vantage • Wed, Feb 27 -
-
-
-
-
-
-
-
Abbott Earnings Preview: What We Are WatchingTrefis • Tue, Jan 22
-
-
-
-
-
-
-
-
-
-
-
-
At These Levels, Covidien Has Room To RunStephen Barnes • Tue, Apr 30
-
-
-
-
-
-
-
-
-
Abbott Laboratories' Management Presents HCV Program Update (Transcript)Mon, Nov 12, 2012
-
Abbott Laboratories Q1 2010 Earnings Call TranscriptWed, Apr 21, 2010
-
Abbott Laboratories Q4 2009 Earnings Call TranscriptWed, Jan 27, 2010
-
Abbott Laboratories, Q3 2009 Earnings Call TranscriptWed, Oct 14, 2009
-
Abbott Laboratories, Q2 2009 Earnings Call TranscriptWed, Jul 15, 2009 • 1 Comment
-
Abbott Laboratories Q1 2009 Earnings Call TranscriptFri, Apr 17, 2009
-
Abbott Laboratories Q4 2008 Earnings Call TranscriptWed, Jan 21, 2009
-
at CNBC.com (May 17, 2013)
-
at CNBC.com (May 17, 2013)
-
at CNBC.com (May 13, 2013)
-
at MarketWatch.com (Apr 30, 2013)
-
at CNBC.com (Apr 29, 2013)
-
at CNBC.com (Apr 22, 2013)
-
at MarketWatch.com (Apr 17, 2013)
-
at MarketWatch.com (Apr 17, 2013)
-
at MarketWatch.com (Apr 17, 2013)
-
at CNBC.com (Apr 17, 2013)
-
at MarketWatch.com (Apr 16, 2013)
-
at CNBC.com (Apr 14, 2013)
-
at CNBC.com (Apr 3, 2013)
-
at CNBC.com (Apr 2, 2013)
-
at MarketWatch.com (Mar 22, 2013)
-
at CNBC.com (Mar 20, 2013)
-
at CNBC.com (Mar 11, 2013)
-
at CNBC.com (Feb 14, 2013)
-
at MarketWatch.com (Jan 30, 2013)
-
at MarketWatch.com (Jan 23, 2013)
ABT vs. ETF Alternatives
Company Description
Abbott Laboratories is an Illinois corporation, incorporated in 1900. Abbott's* principal business is the discovery, development, manufacture, and sale of a broad and diversified line of health care products.
Abbott has four reportable revenue segments: Pharmaceutical Products, Diagnostic... More
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
- Monday, March 11, 3:57 PM Abbott Labs (ABT +0.5%) ticks up after reporting positive trial results for the it's Absorb Bioresorbable Vascular Scaffold. Results showed the rate of major adverse cardiovascular events in 101 patients was 10 percent at three years, similar to comparative data with a best-in-class drug eluting stent at the same follow-up period. Absorb is commercially available in Europe as well as other international markets and is an investigational device in the U.S. Comment! [Healthcare]
- Monday, March 4, 9:50 AM Shares in GSK (GSK -0.6%), Pfizer (PFE +0.3%) and Abbott (ABT +0.2%) show little reaction to news that lamivudine and zidovudine, which they sell in a JV, helped cure a 2/12 year old infant of HIV. Other firms that develop HIV treatments, including Merck (MRK +0.4%), J&J (JNJ +0.35%) and Gilead (GILD +0.3%), also don't seem too impressed. Comment! [Healthcare]
- Monday, March 4, 5:42 AM A 2 1/2 year-old infant appears to have been cured of HIV following aggressive treatment soon after birth with the drugs lamivudine and zidovudine, which are sold by a joint venture between GlaxoSmithKline (GSK), Pfizer (PFE), ViiV Healthcare and Abbott Laboratories' (ABT) Kaletra. The news could revolutionize the way babies with HIV are treated. "It's proof of principle that we can cure HIV infection if we can replicate this case," says Johns Hopkins' Deborah Persaud, the lead author of a report on the case. 5 Comments [Healthcare, Top Stories]
- Friday, February 15, 3:29 PM Abbott Laboratories (ABT) declares $0.14/share quarterly dividend, in line with previous. Forward yield 1.60%. For shareholders of record Apr. 15. Payable May 15. Ex-div date Apr.11. (PR) 1 Comment [Dividends]
- Friday, February 15, 10:43 AM Shares of Abbott Labs (ABT +1%) tick higher after being initiated by analysts at Stifel Nicolaus with a Buy and a price target of $40 per share, noting that the drug giant is a solid performer that delivers reliable and consistent earnings growth. Comment! [Healthcare, On the Move]
- Thursday, January 31, 4:09 PM Despite the marketshare gains Cardiovascular Systems (CSII) has made with its Diamondback and Stealth devices for treating narrowed or blocked arteries in the leg, the real value in the company may lie in its takeout potential, says Seeking Alpha contributor Stephen Simpson. CR Bard, Cook, BSX, JNJ, MDT and ABT all have sales forces in the peripheral treatment space, making them solid candidates for a possible buyout of CSII. Comment! [Healthcare, M&A]
- Wednesday, January 23, 7:51 AM Abbott Labs (ABT): Q4 EPS of $1.51 beats by $0.01. Revenue of $10.84B beats by $0.26B. Shares +3% premarket. (PR) 1 Comment [Earnings, Breaking News, Healthcare, On the Move]
- Wednesday, January 23, 12:05 AM Notable earnings before Wednesday’s open: ABBV, ABT, APD, ATI, BHI, CHKP, COH, DGX, FNFG, GD, LCC, MCD, MSI, NVS, PX, RES, SAP, STJ, TEL, TXT, UTX, WLP Comment! [Earnings]
- Tuesday, January 22, 5:30 PM Notable earnings before Wednesday’s open: ABBV, ABT, APD, ATI, BHI, CHKP, COH, DGX, FNFG, GD, LCC, MCD, MSI, NVS, PX, RES, SAP, STJ, TEL, TXT, UTX, WLP Comment! [Earnings]
- Tuesday, January 8, 7:26 PM Nestle (NSRGY.PK) is looking to sell nearly $1B of its Latin American assets in an effort to secure regulatory approval for its $12B purchase of Pfizer's (PFE) nutrition unit. The company is in the early stages of the process, with the assets potentially drawing interest from H.J. Heinz (HNZ), Danone (DANOY.PK), Abbott Laboratories (ABT) and Mead Johnson Nutrition (MJN). Comment! [Consumer, Global & FX, M&A]
- Thursday, January 3, 5:08 PM Abbott Labs (ABT), Johnson & Johnson (JNJ) and Sanofi (SNY) have all displayed an interest in Warburg Pincus' Bausch & Lomb. Warburg, working through Goldman Sachs (GS), is hoping to get at least $10B for the business and is seeking first-round bids by month’s end. The $10B price tag would be a major coup for Warburg, raking in a 200% return off its $1.7b equity investment. 1 Comment [Healthcare, M&A]
- Thursday, January 3, 9:00 AM Abbott Labs (ABT +0.5%) launches its XIENCE Xpedition drug-eluting coronary stent, which slowly releases a medicine to block cell proliferation, after receiving FDA approval for the device. "XIENCE Xpedition represents a powerful combination of deliverability, strong clinical data and broad availability of meaningful sizes," says Dr Samin Sharma of Mount Sinai Medical Center in New York. (PR) Comment! [Healthcare]
- Thursday, January 3, 8:28 AM BG Medicine (BGMD) rockets 24% after saying it has received the EU's CE mark for the first automated version of the company's Galectin-3 blood test for improving the management of heart conditions. BG is working with four partners to commercialize the test, including Abbott Labs (ABT) and Siemens (SI). The EU approval comes just a week after SA author Robert Fabian called BG Medicine a "hidden gem." (PR) Comment! [Healthcare, On the Move]
- Thursday, January 3, 4:35 AM AbbVie (ABBV) closed at $35.12 yesterday after opening at $34.40 following its spin-off from Abbott Labs (ABT), giving it a market cap of $55.8B vs Abbott's $50.7B. AbbVie faces plenty of challenges, not least reducing its dependence on its $9B-per-year arthritis treatment Humira, which accounts for at least 70% of the company's profit but which will lose its patent protection in 2017. Comment! [Healthcare]
-
Wednesday, January 2, 12:45 PM
Midday top 10 gainers: ZIP +48%. BIOF +28%. STXS +25%. GIGA +21%. FORD +19%. IQNT +20%. EGLE +18%. OTT +18%. GEVO +17%. APAGF +17%.
Midday top 10 Losers: ABT -51%. SKUL -14%. DOLE -13%. TRIT -12%. ATAI -12%. HMNY -9%. CHRM -9%. NTLS -9%. VSCI -8%. MR -8%. 2 Comments [On the Move] -
Wednesday, January 2, 9:10 AM
Premarket gainers: ZIP +47.94%. POL +18.71%. SGYP +16.92%. MCP +9%. JRCC +8.41%. PAL +7.69%. KWK +7.69%. ZGNX +7.52%. PPHM +6.82%. ONTY +6.77%.
Losers: ABT -50%. 6 Comments
-
- View all 1 replies
-
Minutemen: Yeah, RSI is in oversold territory. I'm long ABT so will just ride it out.
-
Derek A. Barrett
Closing $ABT after reaching 50% Graham profit target. Still holding in 401k and also $ABBV in taxable account. - View all 0 replies
-
- View all 3 replies
-
SKS1586: Thanks my friend. I am a Trader. I increase & reduce position frequently. I sell with small profit to create CASH for other opportunities.
-
SKS1586: Rubenov: You are correct. Correction may happen anytime. I work predominantly with Turnarounds + Scale in slowly & remove profit every week.
-
- View all 0 replies
-
- View all 0 replies
-
- View all 2 replies
-
-
SKS1586: joe kelly - I reduce or remove my positions for creation of CASH. Therefore I leave trades with much less profit than most Investors/Traders
-
- View all 0 replies
-
- View all 5 replies
-
Brennan Basnicki: Yah looks like it. I was really bullish, but a few key trend lines probably will be taken out. Will be seeing how $ANR and $WLT react
-
-
- View all 3 replies
-
Brennan Basnicki: No, haven't tried any shorts for a while. Any time I have they have been short term, with recent one's being losers unfortunately!
-
Brennan Basnicki: The chart is actually pretty bullish right now, however I am bearish on fundamentals. In any case, I don't expect to trade it anytime soon
-
- View all 0 replies
LATEST REPLIES
-
- View all 3 replies
-
-
-
- View all 1 replies
-
-
- View all 1 replies
-
-
- View all 1 replies
-
-
- View all 3 replies
-
-
-
- View all 2 replies
-
-
Caiman Valores: YPF won't be paying a dividend, likely to be nationalized by Argentine government, find out more in my article http://bit.ly/ICs5GM
-
- View all 2 replies
-
-
-
- View all 2 replies
-
Hillbilly Stock Star: T London Financial Bullish, mobile payments iWallet, don't know how it works, adding on dips imo. -
-
- View all 2 replies
-
-
-
- View all 3 replies
-
-
Hillbilly Stock Star: Cool,.....Only thing I bought while you were gone was 1K shares of MTDR, spread out thin 20% cash.
-
- View all 1 replies
-
-
The Scientist
Still waiting for a response from AF from The Street on the licensing deals by APRI with ABT and NVS. Shows the value of NexACT technology - View all 1 replies
-
The Scientist: Huge multi-national biotechs do not do licensing deals with microcap biotech's unless they felt the technology is novel.
-
- View all 6 replies
-
-
-
- View all 3 replies
-
-
-
- View all 6 replies
-
-